@article{ref1,
title="Cost-effectiveness of hip fracture prevention",
journal="Epidemiologia e Prevenzione",
year="1998",
author="Visentin, P. and Ciravegna, R. and Corcelli, F. and Fabris, F.",
volume="22",
number="1",
pages="44-48",
abstract="We estimated the Cost Per Avoided Hip Fracture (CPAHF, millions Lira) by osteoporosis treatment, on the basis of a review on randomized controlled trials. Prevention with vitamin D3 in institutionalized elderly women is cost-neutral (CPAHF = -4; 95% CI = -9, +5). Prevention with alendronate in non-institutionalized women screened on bone mineral density generates doubts (CPAHF = 275; 95% CI = 146, 19.426). The cost-effectiveness analyses can strengthen or weaken conclusions of the clinical trials and discourage the use of economically unsustainable preventive treatments whose efficacy is unproven.<p /><p>Language: it</p>",
language="it",
issn="1120-9763",
doi="",
url="http://dx.doi.org/"
}